Abstract: Cytokines, including muteins thereof, which are biologically inactive in humans but remain immunogenic, are used in pharmaceutical compositions to promote a neutralizing immune response against native cytokines when administered to a subject in need thereof to treat homeostatic disorders and disorders associated with an overproduction of cytokines.
Type:
Grant
Filed:
April 27, 2000
Date of Patent:
March 16, 2004
Assignee:
Istituto di Ricerche di Biologia Molecolare P. Angeletti
S.p.A.
Abstract: Hitherto undiscovered 3′ sequence of GBV confers infectivity in tamarins on otherwise non-infective GBV genome. HCV sequences may be substituted within an infective GBV genome to provide for in vivo assays for agents able to modulate HCV activity.
Type:
Grant
Filed:
May 25, 2000
Date of Patent:
September 30, 2003
Assignee:
Istituto di Ricerche di Biologia Molecolare P. Angeletti
S.p.A.
Abstract: The present invention refers to the use of hCNTF (human ciliary neurotrophic factor), mutants thereof or other molecules that activate the CNTF receptor, for the preparation of drugs for the treatment of obesity and associated diseases, for example hyperglycemia. FIG. 1 shows the anti-obesity effect of hCNTF and leptin on body weight (left panels) and on food intake (right panels) in genetically obese mice and in mice with diet-induced obesity (DIO).
Type:
Application
Filed:
January 31, 2003
Publication date:
September 18, 2003
Applicant:
Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
Inventors:
Gennaro Ciliberto, Isabelle Gloaguen, Annalise Di Marco, Anna Demartis, Ralph Laufer, Riccardo Cortese
Abstract: The present invention refers to the use of hCNTF (human ciliary neurotrophic factor), mutants thereof or other molecules that activate the CNTF receptor, for the preparation of drugs for the treatment of obesity and associated disease, for example hyperglycemia. FIG. 1 shows the anti-obesity effect of hCNTF and leptin on body weight (left panels) and on food intake (right panels) in genetically obese mice and in mice with diet-induced obesity (DIO).
Type:
Grant
Filed:
July 19, 1999
Date of Patent:
May 20, 2003
Assignee:
Istituto di Ricerche di Biologia Molecolare P. Angeletti
S.p.A.
Inventors:
Gennaro Ciliberto, Patrizia Costa, Giacomo Paonessa, Domenico Lazzaro, Isabelle Gloaguen, Annalise Di Marco, Anna De Martis, Ralph Laufer, Riccardo Cortese
Abstract: Adenoviral particles are produced by incubating cells containing a helper adenovirus vector and a helper-dependent adenoviral vector including an Adeno-Associated Virus (AAV) rep gene, such as rep 78. Cells are provided containing a helper adenovirus vector. A helper-dependent adenoviral vector including an AAV rep gene is introduced into the cells, for instance by infection with infective viral particles. The cells are incubated to produce adenoviral particles containing nucleic acid including the AAV rep gene. Advantageously, cells containing helper adenovirus vector are pre-incubated for 0.5-12 hours, preferably about 4 hours, to allow expression of viral proteins required for adenoviral genome replication before introducing the helper-dependent adenovirus vector including an AAV rep gene.
Type:
Grant
Filed:
December 8, 2000
Date of Patent:
February 18, 2003
Assignee:
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti
S.p.A.
Inventors:
Gennaro Ciliberto, Stefano Colloca, Nicola La Monica
Abstract: The present invention relates to the molecular biology and virology of the hepatitis C virus (HCV). An object of the present invention is a method to reproduce in vitro the RNA-dependent RNA polymerase activity of HCV that makes use of sequences contained in the HCV NS5B protein.
Type:
Application
Filed:
February 27, 2002
Publication date:
November 7, 2002
Applicant:
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A
Inventors:
Raffaele De Francesco, Licia Tomei, Sven-Erik Behrens
Abstract: It is known that the ligands of the group of cytokines similar to Interleuk 6 (IL-6), that is Oncostatin M (OSM), Leukemia Inhibitory Factor (LIF), Ciliary Neurotrophic Factor (CNTF) and Interleukin 11 (IL-11), induce the formation of a receptor complex of which the membrane molecule gp 130 is a part. The present invention refers to a methodology for selecting superagonists, antagonists and superantagonists of human interleukin-6 comprising the following operations: comparing the amino acid sequence of bovine granulocyte colony stimulating factor (bG-CSF) with the sequence of said hormone; and on the basis of the above comparison, formulating a three dimensional model of said hormone, which allows the identification of residues that form the site of interaction with the specific receptor (Site 1) and those that constitute the site of interaction with gp 130 (Site 2) respectively.
Type:
Grant
Filed:
January 16, 1998
Date of Patent:
June 22, 1999
Assignee:
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A.
Inventors:
Gennaro Ciliberto, Rocco Savino, Armin Lahm, Carlo Toniatti
Abstract: It is known that the ligands of the group of cytokines similar to Interleukin 6 (IL-6), that is Oncostatin M (OSM), Leukemia Inhibitory Factor (LIF), Ciliary Neurotrophic Factor (CNTF) and Interleukin 11 (IL-11), induce the formation of a receptor complex of which the membrane molecule gp 130 is a part. The present invention refers to a methodology for selecting superagonists, antagonists and superantagonists of human interleukin-6 comprising the following operations: comparing the amino acid sequence of bovine granulocyte colony stimulating factor (bG-CSF) with the sequence of said hormone; and on the basis of the above comparison, formulating a three dimensional model of said hormone, which allows the identification of residues that form the site of interaction with the specific receptor (Site 1) and those that constitute the site of interaction with gp 130 (Site 2) respectively.
Type:
Grant
Filed:
August 14, 1996
Date of Patent:
December 15, 1998
Assignee:
Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
Inventors:
Gennaro Ciliberto, Rocco Savino, Armin Lahm, Carlo Toniatti